Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Cartilage (msm)

G.Papanikolaou Research Group

Status and phase: Unknown; Phase 1

Conditions: Osteoarthritis

Treatments: Drug: Placebo; Drug: MethylSulfonylMethane (MSM)

Study type: Interventional

Funder types: Other

Identifiers

NCT01836757

msm2012

Details and patient eligibility

About

To delineate the effect of MSM on osteoarthritis

Full description

Objective: To delineate the effect of MSM on osteoarthritis of large joints. Design: Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA to be divided in 2 groups. Intervention is either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured are the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC), patient and physician assessments and SF-36 (overall health-related quality of life).

Enrollment: 100 estimated patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Knee and hip OA
• men and women >45 years of age

Exclusion criteria

• any other type of arthritis
• chronic pain syndrome
• arthroscopic surgery in the past 8 months
• intra-articular corticosteroidsin the past 8 months
• hyaluronic acid injections in the past 8 months
• narcotic pain killers use
• renal or hepatic disease
• body mass index (BMI) >45 kg/m2
• cancer

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

100 participants in 2 patient groups, including a placebo group

MSM group

Experimental group

Description:

Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)

Treatment:

Drug: MethylSulfonylMethane (MSM)

Placebo Group

Placebo Comparator group

Description:

Placebo 3 gr twice a day for 26 weeks (6 gr/day total)

Treatment:

Drug: Placebo